Status:
COMPLETED
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
30-75 years
Phase:
PHASE3
Brief Summary
The aim of this study is to assess the long-term safety of exenatide in patients with type 2 diabetes who were treated with exenatide in Study H8O-MC-GWAA (6-month study) or Study H8O-MC-GWAD (12-mont...
Eligibility Criteria
Inclusion
- Patients received exenatide therapy in Study H8O-MC-GWAA or Study H8O-MC-GWAD and completed the respective study.
Exclusion
- Patients were excluded or discontinued early from Study H8O-MC-GWAA or Study H8O-MC-GWAD.
- Patients have received treatment within the last 30 days with a drug, not including exenatide, that has not received regulatory approval for any indication at the time of study entry.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT01876849
Start Date
December 1 2003
End Date
July 1 2008
Last Update
February 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Renton, Washington, United States